Sino Biopharmaceutical (01177.HK) opened over 5% higher in Hong Kong trading. At press time, shares gained 1.88% to HK$6.49 with turnover reaching HK$706 million.
The pharmaceutical giant announced a $500 million deal to acquire 95.09% equity in Shanghai Laixin Pharmaceuticals. Combined with its existing 4.91% stake obtained during Laixin's Series C funding, this transaction will make Laixin a wholly-owned subsidiary of Sino Biopharmaceutical.
Industry records reveal Laixin's significant licensing achievements: In May 2023, AstraZeneca secured exclusive global rights to develop and commercialize LM-305, involving $55 million upfront payment plus potential milestones up to $545 million. By November 2024, Merck & Co. obtained worldwide rights to PD-1/VEGF bispecific antibody LM-299, generating total proceeds of $3.288 billion including $888 million upfront payment and technology transfer milestones.
To date, Shanghai Laixin Pharmaceuticals has out-licensed nearly $4 billion worth of assets, equivalent to approximately ¥30 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.